Intercepting pelvic cancer in the distal fallopian tube: Theories and realities

Molecular Oncology

Volumn 3, Issue 2, 2009, Pages 165-170

  Crum, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRCA; Intraepithelial carcinoma; Ovarian carcinoma; p53; Serous carcinoma

Indexed keywords

PROTEIN P53;

CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; EARLY CANCER; GENE MUTATION; HUMAN; ONCOGENE; OVARY CARCINOMA; PELVIS CANCER; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; UTERINE TUBE CARCINOMA;

FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; PELVIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63549123345     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.01.004     Document Type: Review

References (30)

1. American Cancer Society. Cancer Facts and Figures (2007). www.cancer.org
2. Ambros R.A., Sherman M.E., Zahn C.M., Bitterman P., and Kurman R.J. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum. Pathol. 26 11 (1995 Nov) 1260-1267
3. Bannatyne P., and Russell P. Early adenocarcinoma of the fallopian tubes. A case for multifocal tumorigenesis. Diagn. Gynecol. Obstet. 3 (1981) 49-60
4. Barakat R.R., Federici M.G., Saigo P.E., Robson M.E., Offit K., and Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 89 2 (2000 Jul 15) 383-390
5. Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A., Garber J.E., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 25 25 (2007 Sep 1) 3985-3990
6. Carlson J.W., Miron A., Jarboe E.A., Parast M.M., Hirsch M.S., Lee Y., et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 26 25 (2008 Sep 1) 4160-4165
7. Cass I., Holschneider C., Datta N., Barbuto D., Walts A.E., and Karlan B.Y. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet. Gynecol. 106 6 (2005 Dec) 1327-1334
8. Eifel P.J., Ross J., Hendrickson M., Cox R.S., Kempson R., and Martinez A. Adenocarcinoma of the endometrium. analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 52 6 (1983 Sep 15) 1026-1031
9. Finch A., Shaw P., Rosen B., Murphy J., Narod S.A., and Colgan T.J. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 100 1 (2006 Jan) 58-64
10. Folkins A.K., Jarboe E.A., Saleemuddin A., Lee Y., Callahan M.J., Drapkin R., et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 109 2 (2008 May) 168-173
11. Hartley A., Rollason T., and Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin. Oncol. (R. Coll. Radiol.) 12 (2000) 58-59
12. Hutson R., Ramsdale J., and Wells M. P53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 27 4 (1995 Oct) 367-371
13. Jarboe E., Folkins A., Nucci M.R., Kindelberger D., Drapkin R., Miron A., et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 27 1 (2008 Jan) 1-9
14. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31 2 (2007 Feb) 161-169
15. Kohler M.F., Berchuck A., Davidoff A.M., Humphrey P.A., Dodge R.K., Iglehart J.D., et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 52 6 (1992 Mar 15) 1622-1627
16. Lancaster J.M., Powell C.B., Kauff N.D., Cass I., Chen L.M., Lu K.H., et al. Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol. 107 2 (2007 Nov) 159-162
17. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211 1 (2007 Jan) 26-35
18. Leeper K., Garcia R., Swisher E., Goff B., Greer B., and Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 1 (2002 Oct) 52-56
19. Piek J.M., van Diest P.J., Zweemer R.P., Jansen J.W., Poort-Keesom R.J., Menko F.H., et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195 4 (2001 Nov) 451-456
20. Piek J.M., Torrenga B., Hermsen B., Verheijen R.H., Zweemer R.P., Gille J.J., et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam. Cancer 2 2 (2003) 73-78
21. Powell C.B., Kenley E., Chen L.M., Crawford B., McLennan J., Zaloudek C., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23 1 (2005 Jan 1) 127-132
22. Shih I., and Kurman R.J. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164 5 (2004 May) 1511-1518
23. Singer G., Stohr R., Cope L., Dehari R., Hartmann A., Cao D.F., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 29 2 (2005 Feb) 218-224
24. Sherman M.E., Bur M.E., and Kurman R.J. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 26 11 (1995 Nov) 1268-1274
25. Stewart S.L., Wike J.M., Foster S.L., and Michaud F. The incidence of primary fallopian tube cancer in the united states. Gynecol. Oncol. 107 3 (2007 Dec) 392-397
26. Saleemuddin A., Folkins A.K., Garrett L., Garber J., Muto M.G., Crum C.P., et al. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol. Oncol. (2008 Aug 20)
27. Salvador S., Rempel A., Soslow R.A., Gilks B., Huntsman D., and Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol. Oncol. 110 3 (2008 Sep) 408-417
28. Tashiro H., Isacson C., Levine R., Kurman R.J., Cho K.R., and Hedrick L. P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150 1 (1997 Jan) 177-185
29. Wheeler D.T., Bell K.A., Kurman R.J., and Sherman M.E. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am. J. Surg. Pathol. 24 6 (2000 Jun) 797-806
30. Zheng W., Khurana R., Farahmand S., Wang Y., Zhang Z.F., and Felix J.C. P53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am. J. Surg. Pathol. 22 12 (1998 Dec) 1463-1473